| Literature DB >> 33322971 |
Rofida Albash1, Carol Yousry2, Abdulaziz Mohsen Al-Mahallawi2,3, Ahmed Adel Alaa-Eldin4.
Abstract
In this investigation, we focused on ceramide IIIB, a skin component whose depletion tends to augment multiple skin disorders and fungal infections. Ceramide IIIB was included into PEGylated surfactant-based vesicular phospholipid system to formulate 'PEGylated cerosomes' (PCs) loaded with fenticonazole nitrate (FTN). FTN is a potent antifungal agent adopted in the treatment of mixed mycotic and bacterial infections. The ceramide content of the vesicles may provide protective and regenerative skin activity whereas Brij®; the PEGylated surfactant, can enhance drug deposition and skin hydration. Both components are expected to augment the topical effect of FTN. PCs were prepared by thin-film hydration technique. A 23 full-factorial design was applied to study the effect of ceramide amount (X1), Brij type (X2) and Brij amount (X3) on the physicochemical properties of the formulated PCs namely; entrapment efficiency (EE%;Y1), particle size (PS;Y2), polydispersity index (PDI;Y3) and zeta potential (ZP;Y4). The optimal formula was selected for further in-vivo dermatokinetic and histopathological study. The optimal FTN-loaded PC (PC6) showed nanosized cerosomes (551.60 nm) with high EE% (83.00%w/w), and an acceptable ZP value of 20.90 mV. Transmission electron micrographs of the optimal formula illustrated intertwined tubulation form deviated from the conventional spherical vesicles. Finally, the dermatokinetic study of PC6 showed higher drug concentration and localization of FTN in skin layers when compared with FTN suspension and the histopathological study confirmed its safety for topical application. The overall findings of our study verified the effectiveness of utilizing PEGylated cerosomes to augment the activity of FTN as a topical antifungal agent.Entities:
Keywords: Brij® ; Ceramide; Fenticonazole nitrate; PEGylated cerosomes; dermatokinetic study; histopathological study
Year: 2021 PMID: 33322971 PMCID: PMC7744155 DOI: 10.1080/10717544.2020.1859000
Source DB: PubMed Journal: Drug Deliv ISSN: 1071-7544 Impact factor: 6.419
The levels of the independent variables in a 23 full-factorial design for the evaluation of FTN-loaded PCs and the optimization criterion for the dependent variables.
| Factors (independent variables) | Levels | |
|---|---|---|
| Low | High | |
| X1: Ceramide amount (mg) | 15 | 30 |
| X2: Brij type | Brij52 | Brij97 |
| X3: Brij amount (mg) | 5 | 15 |
| Responses (dependent variables) | Constraints | |
| Y1: EE (%) | Maximize | |
| Y2: PS (nm) | Minimize | |
| Y3: PDI | – | |
| Y4: ZP | Maximize | |
EE%: entrapment efficiency percent; FTN: fenticonazole nitrate; PS: particle size; PDI: polydispersity index; ZP: zeta potential; PCs: PEGylated cerosomes.
Experimental runs composition corresponding to the 23 full factorial design for FTN-loaded PC formulation and their resultant dependent variables.
| Ceramide amount (mg) | Brij type | Brij amount (mg) | EE% | PS (nm) | PDI | ZP (mV) | |
|---|---|---|---|---|---|---|---|
| PC1 | 15 | Brij 52 | 5 | 85.33 ± 1.24 | 458.00 ± 18.00 | 0.51 ± 0.03 | 18.50 ± 0.28 |
| PC2 | 30 | 99.33 ± 0.48 | 630.00 ± 9.20 | 0.53 ± 0.05 | 11.00 ± 0.38 | ||
| PC3 | 15 | Brij 97 | 82.66 ± 1.25 | 336.6 ± 12.35 | 0.50 ± 0.06 | 16.70 ± 0.35 | |
| PC4 | 30 | 92.33 ± 1.25 | 422.00 ± 21.96 | 0.84 ± 0.03 | 2.74 ± 0.13 | ||
| PC5 | 15 | Brij 52 | 15 | 77.00 ± 0.81 | 309.20 ± 9.06 | 0.56 ± 0.03 | 14.30 ± 0.14 |
| PC6 | 30 | 83.00 ± 1.63 | 551.60 ± 23.84 | 0.44 ± 0.05 | 20.90 ± 0.55 | ||
| PC7 | 15 | Brij 97 | 69.66 ± 0.47 | 361.50 ± 20.34 | 0.71 ± 0.07 | 2.80 ± 0.09 | |
| PC8 | 30 | 78.33 ± 2.86 | 392.50 ± 8.65 | 0.57 ± 0.02 | 7.92 ± 0.17 |
Data represented as mean ± SD (n = 3). EE%: entrapment efficiency percentage; FTN: fenticonazole nitrate; PS: particle size; PDI: polydispersity index; PC: PEGylated cerosomes.
Output data of the 23 full factorial design implemented for optimizing PCs formulations with the predicted and observed values for the optimal FTN-loaded PC (PC6).
| Responses | EE% | PS (nm) | ZP (mV) |
|---|---|---|---|
| Adjusted | 0.94 | 0.94 | 0.98 |
| Predicted | 0.89 | 0.90 | 0.978 |
| Adequate precision | 20.58 | 20.11 | 38.09 |
| Significant factors | X1, X2, X3 | X1, X2, X3, | X1, X2 |
| Observed value of optimal formula (PC6) | 83 | 551.6 | 20.9 |
| Predicted value of optimal formula (PC6) | 85.18 | 575.52 | 21.03 |
EE%: entrapment efficiency percentage; PS: particle size; PDI: polydispersity index; ZP: zeta potential; PC: PEGylated cerosomes..
Figure 1.3D surface plots for the effect of ceramide amount (X1), Brij type (X2) and Brij amount (X3) on EE% (A-C), PS (D-F) and ZP (G-I) of FTN loaded PCs. EE%: entrapment efficiency percent; PS: particle size; PDI: polydispersity index; ZP: zeta potential; FTN: fenticonazole nitrate; PC: PEGylated cerosomes.
Figure 2.Transmission electron micrograph of the optimal FTN-loaded PEGylated Cerosomes (PC6).
Figure 3.Mean (±SD) skin-FTN concentration following topical application of the optimal FTN-loaded PC (PC6) and FTN suspension to 18 Wistar rat each. FTN: fenticonazole nitrate; PC: PEGylated cerosomes. Data represented as mean ± SD (n = 3).
Figure 4.Photomicrographs showing histopathological sections (hematoxylin and eosin stained) of rat’s skin normal control (group I) and rat’s skin treated with PC6 (group II) with magnification power of 16x to illustrate all skin layers (A) and magnification power of 40x to identify the epidermis and dermis (B). E: epidermis; D: dermis; HF: hair follicles; FTN: fenticonazole nitrate; PC: PEGylated cerosomes.